FDA Approved: EXPAREL — Supplemental Application (Pacira Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for EXPAREL (bupivacaine) by Pacira Pharmaceuticals, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postoperative Pain

Drugs mentioned

• Exparel (liposomal bupivacaine)

Snippet

SUPPL AP for EXPAREL (BUPIVACAINE)